{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T16:13:49Z","timestamp":1790957629322,"version":"4.1.0"},"reference-count":203,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100002850","name":"Fondo Nacional de Desarrollo Cient\u00edfico y Tecnol\u00f3gico","doi-asserted-by":"publisher","award":["1180157"],"award-info":[{"award-number":["1180157"]}],"id":[{"id":"10.13039\/501100002850","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002850","name":"Fondo Nacional de Desarrollo Cient\u00edfico y Tecnol\u00f3gico","doi-asserted-by":"publisher","award":["1190743"],"award-info":[{"award-number":["1190743"]}],"id":[{"id":"10.13039\/501100002850","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002850","name":"Fondo Nacional de Desarrollo Cient\u00edfico y Tecnol\u00f3gico","doi-asserted-by":"publisher","award":["1220392"],"award-info":[{"award-number":["1220392"]}],"id":[{"id":"10.13039\/501100002850","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002850","name":"Fondo Nacional de Desarrollo Cient\u00edfico y Tecnol\u00f3gico","doi-asserted-by":"publisher","award":["3210496"],"award-info":[{"award-number":["3210496"]}],"id":[{"id":"10.13039\/501100002850","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005853","name":"Universidad de Chile","doi-asserted-by":"publisher","award":["CRP-ICGEB CHL18-04"],"award-info":[{"award-number":["CRP-ICGEB CHL18-04"]}],"id":[{"id":"10.13039\/501100005853","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005853","name":"Universidad de Chile","doi-asserted-by":"publisher","award":["URG-035\/1"],"award-info":[{"award-number":["URG-035\/1"]}],"id":[{"id":"10.13039\/501100005853","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100020884","name":"Agencia Nacional de Investigaci\u00f3n y Desarrollo","doi-asserted-by":"publisher","award":["FONDAP 15130011"],"award-info":[{"award-number":["FONDAP 15130011"]}],"id":[{"id":"10.13039\/501100020884","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.bcp.2022.115183","type":"journal-article","created":{"date-parts":[[2022,7,20]],"date-time":"2022-07-20T21:36:15Z","timestamp":1658352975000},"page":"115183","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"special_numbering":"C","title":["Angiotensin-(1\u20139) in hypertension"],"prefix":"10.1016","volume":"203","author":[{"given":"Ignacio","family":"Norambuena-Soto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camila","family":"Lopez-Crisosto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javiera","family":"Martinez-Bilbao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"Hernandez-Fuentes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Parra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Lavandero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Chiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcp.2022.115183_b0005","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1111\/j.1748-1716.1898.tb00272.x","article-title":"Niere und Kreislauf1","volume":"8","author":"Tigerstedt","year":"1898","journal-title":"Skandinavisches Archiv F\u00fcr Physiologie."},{"key":"10.1016\/j.bcp.2022.115183_b0010","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1146\/annurev.ph.40.030178.002113","article-title":"The renin-angiotensin system","volume":"40","author":"Reid","year":"1978","journal-title":"Annu. Rev. Physiol."},{"key":"10.1016\/j.bcp.2022.115183_b0015","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1080\/080370501753400638","article-title":"The renin-angiotensin system in the twenty-first century","volume":"10","author":"Nicholls","year":"2001","journal-title":"Blood Press."},{"key":"10.1016\/j.bcp.2022.115183_b0020","unstructured":"J.H. Fountain, S.L. Lappin, Physiology, Renin Angiotensin System, StatPearls, Treasure Island (FL), 2022."},{"key":"10.1016\/j.bcp.2022.115183_b0025","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.tips.2004.08.007","article-title":"Chymase as a novel target for the prevention of vascular diseases","volume":"25","author":"Takai","year":"2004","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.bcp.2022.115183_b0030","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1161\/01.CIR.0000074786.92067.AA","article-title":"Role for chymase in heart failure: angiotensin II-dependent or -independent mechanisms?","volume":"107","author":"Kokkonen","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.bcp.2022.115183_b0035","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1161\/HYPERTENSIONAHA.118.10266","article-title":"Understanding Angiotensin II Type 1 Receptor Signaling in Vascular Pathophysiology","volume":"71","author":"Eguchi","year":"2018","journal-title":"Hypertension"},{"key":"10.1016\/j.bcp.2022.115183_b0040","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1111\/j.1365-2796.2008.01981.x","article-title":"Renin-angiotensin system revisited","volume":"264","author":"Fyhrquist","year":"2008","journal-title":"J. Intern. Med."},{"key":"10.1016\/j.bcp.2022.115183_b0045","first-page":"683","article-title":"The Renin-Angiotensin System in Hypertension, a Constantly Renewing Classic: Focus on the Angiotensin AT2-Receptor","volume":"36","author":"Assersen","year":"2020","journal-title":"Can. J. Cardiol."},{"key":"10.1016\/j.bcp.2022.115183_b0050","doi-asserted-by":"crossref","first-page":"492","DOI":"10.2174\/1381612826666200115092015","article-title":"Emerging Role of Angiotensin AT2 Receptor in Anti-Inflammation: An Update","volume":"26","author":"Patel","year":"2020","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.bcp.2022.115183_b0055","doi-asserted-by":"crossref","DOI":"10.1111\/apha.13280","article-title":"Anti-fibrotic mechanisms of angiotensin AT2 -receptor stimulation","volume":"227","author":"Sumners","year":"2019","journal-title":"Acta Physiol (Oxf)."},{"key":"10.1016\/j.bcp.2022.115183_b0060","doi-asserted-by":"crossref","unstructured":"S. Martinez-Meza, J. Diaz, A. Sandoval-Borquez, M. Valenzuela-Valderrama, N. Diaz-Valdivia, V. Rojas-Celis, et al., AT2 Receptor Mediated Activation of the Tyrosine Phosphatase PTP1B Blocks Caveolin-1 Enhanced Migration, Invasion and Metastasis of Cancer Cells, Cancers (Basel). 2019;11. http:\/\/dx.doi.org\/10.3390\/cancers11091299.","DOI":"10.3390\/cancers11091299"},{"issue":"2","key":"10.1016\/j.bcp.2022.115183_b0065","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1161\/01.ATV.0000253889.09765.5f","article-title":"Mass-spectrometric identification of a novel angiotensin peptide in human plasma","volume":"27","author":"Jankowski","year":"2007","journal-title":"Arterioscler. Thromb.. Vasc. Biol."},{"key":"10.1016\/j.bcp.2022.115183_b0070","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.peptides.2013.04.014","article-title":"Angiotensin III: a physiological relevant peptide of the renin angiotensin system","volume":"46","author":"Yugandhar","year":"2013","journal-title":"Peptides"},{"issue":"1","key":"10.1016\/j.bcp.2022.115183_b0075","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00441-002-0655-3","article-title":"Angiotensin IV in the central nervous system","volume":"311","author":"von Bohlen und Halbach","year":"2003","journal-title":"Cell Tissue Res."},{"key":"10.1016\/j.bcp.2022.115183_b0080","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.tcm.2006.10.003","article-title":"The regulation of the inflammatory response through nuclear factor-kappab pathway by angiotensin IV extends the role of the renin angiotensin system in cardiovascular diseases","volume":"17","author":"Ruiz-Ortega","year":"2007","journal-title":"Trends Cardiovasc. Med."},{"key":"10.1016\/j.bcp.2022.115183_b0085","doi-asserted-by":"crossref","first-page":"23612","DOI":"10.1074\/jbc.270.40.23612","article-title":"Cloning and characterization of a novel insulin-regulated membrane aminopeptidase from Glut4 vesicles","volume":"270","author":"Keller","year":"1995","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bcp.2022.115183_b0090","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1006\/frne.1995.1002","article-title":"The angiotensin IV system: functional implications","volume":"16","author":"Wright","year":"1995","journal-title":"Front. Neuroendocrinol."},{"key":"10.1016\/j.bcp.2022.115183_b0095","doi-asserted-by":"crossref","first-page":"111119","DOI":"10.1016\/j.mce.2020.111119","article-title":"The Angiotensin-(1\u201312)\/Chymase axis as an alternate component of the tissue renin angiotensin system","volume":"529","author":"Ferrario","year":"2021","journal-title":"Mol. Cell. Endocrinol."},{"key":"10.1016\/j.bcp.2022.115183_b0100","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1080\/10641963.2017.1377218","article-title":"Hypertension regulating angiotensin peptides in the pathobiology of cardiovascular disease","volume":"40","author":"Hussain","year":"2018","journal-title":"Clin. Exp. Hypertens."},{"issue":"5","key":"10.1016\/j.bcp.2022.115183_b0105","doi-asserted-by":"crossref","DOI":"10.1161\/01.RES.87.5.e1","article-title":"A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1\u20139","volume":"87","author":"Donoghue","year":"2000","journal-title":"Circ. Res."},{"issue":"2","key":"10.1016\/j.bcp.2022.115183_b0110","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/s41569-019-0244-8","article-title":"Counter-regulatory renin-angiotensin system in cardiovascular disease","volume":"17","author":"Paz Ocaranza","year":"2020","journal-title":"Nat. Rev. Cardiol."},{"issue":"7","key":"10.1016\/j.bcp.2022.115183_b0115","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1016\/j.peptides.2005.01.009","article-title":"Organ-specific distribution of ACE2 mRNA and correlating peptidase activity in rodents","volume":"26","author":"Gembardt","year":"2005","journal-title":"Peptides"},{"issue":"5","key":"10.1016\/j.bcp.2022.115183_b0120","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1016\/j.cell.2020.04.035","article-title":"SARS-CoV-2 Receptor ACE2 Is an Interferon-Stimulated Gene in Human Airway Epithelial Cells and Is Detected in Specific Cell Subsets across Tissues","volume":"181","author":"Ziegler","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.bcp.2022.115183_b0125","doi-asserted-by":"crossref","first-page":"3067","DOI":"10.1681\/ASN.2006050423","article-title":"Glomerular localization and expression of Angiotensin-converting enzyme 2 and Angiotensin-converting enzyme: implications for albuminuria in diabetes","volume":"17","author":"Ye","year":"2006","journal-title":"J. Am. Soc. Nephrol."},{"issue":"4","key":"10.1016\/j.bcp.2022.115183_b0130","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1093\/eurheartj\/ehi114","article-title":"Myocardial infarction increases ACE2 expression in rat and humans","volume":"26","author":"Burrell","year":"2005","journal-title":"Eur. Heart J."},{"issue":"5","key":"10.1016\/j.bcp.2022.115183_b0135","doi-asserted-by":"crossref","first-page":"R370","DOI":"10.1152\/ajpregu.00366.2014","article-title":"Brain ACE2 overexpression reduces DOCA-salt hypertension independently of endoplasmic reticulum stress","volume":"308","author":"Xia","year":"2015","journal-title":"Am. J. Physiol. Regul. Integr. Comp. Physiol."},{"key":"10.1016\/j.bcp.2022.115183_b0140","article-title":"ACE2 Expression in Kidney and Testis May Cause Kidney and Testis Infection in COVID-19 Patients","volume":"7","author":"Fan","year":"2020","journal-title":"Front. Med. (Lausanne)."},{"key":"10.1016\/j.bcp.2022.115183_b0145","doi-asserted-by":"crossref","first-page":"H1013","DOI":"10.1152\/ajpheart.00068.2005","article-title":"Angiotensin II AT1 receptors regulate ACE2 and angiotensin-(1\u20137) expression in the aorta of spontaneously hypertensive rats","volume":"289","author":"Igase","year":"2005","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"10.1016\/j.bcp.2022.115183_b0150","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.yjmcc.2013.11.017","article-title":"Angiotensin II induced proteolytic cleavage of myocardial ACE2 is mediated by TACE\/ADAM-17: a positive feedback mechanism in the RAS","volume":"66","author":"Patel","year":"2014","journal-title":"J. Mol. Cell. Cardiol."},{"key":"10.1016\/j.bcp.2022.115183_b0155","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1113\/expphysiol.2007.040352","article-title":"Angiotensin-converting enzyme 2 catalytic activity in human plasma is masked by an endogenous inhibitor","volume":"93","author":"Lew","year":"2008","journal-title":"Exp. Physiol."},{"key":"10.1016\/j.bcp.2022.115183_b0160","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1042\/bj2060211","article-title":"Early events in the response of fast skeletal muscle to chronic low-frequency stimulation. Polyamine biosynthesis and protein phosphorylation","volume":"206","author":"Mastri","year":"1982","journal-title":"Biochem. J."},{"issue":"17","key":"10.1016\/j.bcp.2022.115183_b0165","doi-asserted-by":"crossref","first-page":"14838","DOI":"10.1074\/jbc.M200581200","article-title":"Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase","volume":"277","author":"Vickers","year":"2002","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bcp.2022.115183_b0170","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s11906-014-0433-0","article-title":"New components of the renin-angiotensin system: alamandine and the MAS-related G protein-coupled receptor D","volume":"16","author":"Etelvino","year":"2014","journal-title":"Curr. Hypertens Rep."},{"key":"10.1016\/j.bcp.2022.115183_b0175","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1253\/circj.CJ-16-0958","article-title":"Differences in Cardiovascular Responses to Alamandine in Two-Kidney, One Clip Hypertensive and Normotensive Rats","volume":"81","author":"Soltani Hekmat","year":"2017","journal-title":"Circ. J."},{"issue":"5","key":"10.1016\/j.bcp.2022.115183_b0180","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1097\/HJH.0b013e328335d291","article-title":"Angiotensin-(1\u20139) regulates cardiac hypertrophy in vivo and in vitro","volume":"28","author":"Ocaranza","year":"2010","journal-title":"J. Hypertens."},{"issue":"13","key":"10.1016\/j.bcp.2022.115183_b0185","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1002\/jssc.201801276","article-title":"Simultaneous determination of nine trace concentration angiotensin peptides in human serum using ultra high performance liquid chromatography with tandem mass spectrometry with sephadex LH-20 gel solid-phase extraction","volume":"42","author":"Shen","year":"2019","journal-title":"J. Sep. Sci."},{"key":"10.1016\/j.bcp.2022.115183_b0190","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1161\/01.HYP.18.6.763","article-title":"Differential regulation of angiotensin peptide levels in plasma and kidney of the rat","volume":"18","author":"Campbell","year":"1991","journal-title":"Hypertension"},{"key":"10.1016\/j.bcp.2022.115183_b0195","first-page":"83","article-title":"Disminuci\u00f3n de la actividad de la ECA2 (enzima convertidora de angiotensina I hom\u00f3loga) en la disfunci\u00f3n ventricular izquierda post infarto al miocardio en la rata","volume":"24","author":"Ocaranza","year":"2005","journal-title":"Rev. Chil. Cardiol."},{"issue":"6891","key":"10.1016\/j.bcp.2022.115183_b0200","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1038\/nature00786","article-title":"Angiotensin-converting enzyme 2 is an essential regulator of heart function","volume":"417","author":"Crackower","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2022.115183_b0205","first-page":"480","article-title":"Menor expresi\u00f3n de la enzima convertidora de angiotensina hom\u00f3loga ECA2 se asocia a mayor remodelamiento de pared a\u00f3rtica de ratas con niveles gen\u00e9ticamente elevados de angiotensina II","volume":"27","author":"Ocaranza","year":"2008","journal-title":"Rev. Chil. Cardiol."},{"issue":"2","key":"10.1016\/j.bcp.2022.115183_b0210","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1161\/HYPERTENSIONAHA.111.177485","article-title":"Angiotensin-(1\u20139) attenuates cardiac fibrosis in the stroke-prone spontaneously hypertensive rat via the angiotensin type 2 receptor","volume":"59","author":"Flores-Munoz","year":"2012","journal-title":"Hypertension"},{"key":"10.1016\/j.bcp.2022.115183_b0215","doi-asserted-by":"crossref","first-page":"114190","DOI":"10.1016\/j.bcp.2020.114190","article-title":"Angiotensin-(1\u20139) prevents vascular remodeling by decreasing vascular smooth muscle cell dedifferentiation through a FoxO1-dependent mechanism","volume":"180","author":"Norambuena-Soto","year":"2020","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bcp.2022.115183_b0220","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.bcp.2018.08.045","article-title":"Angiotensin-(1\u20139) reduces cardiovascular and renal inflammation in experimental renin-independent hypertension","volume":"156","author":"Gonzalez","year":"2018","journal-title":"Biochem. Pharmacol."},{"issue":"4","key":"10.1016\/j.bcp.2022.115183_b0225","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1097\/HJH.0000000000000094","article-title":"Angiotensin-(1\u20139) reverses experimental hypertension and cardiovascular damage by inhibition of the angiotensin converting enzyme\/Ang II axis","volume":"32","author":"Ocaranza","year":"2014","journal-title":"J. Hypertens."},{"key":"10.1016\/j.bcp.2022.115183_b0230","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.lfs.2013.10.020","article-title":"Stimulation of ANP by angiotensin-(1\u20139) via the angiotensin type 2 receptor","volume":"93","author":"Cha","year":"2013","journal-title":"Life Sci."},{"key":"10.1016\/j.bcp.2022.115183_b0235","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1097\/HJH.0000000000000246","article-title":"Dissociating angiotensin 1\u20139 anticardiovascular remodeling effects from those on blood pressure","volume":"32","author":"Calo","year":"2014","journal-title":"J. Hypertens."},{"issue":"4","key":"10.1016\/j.bcp.2022.115183_b0240","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1111\/jvim.15548","article-title":"Plasma and tissue angiotensin-converting enzyme 2 activity and plasma equilibrium concentrations of angiotensin peptides in dogs with heart disease","volume":"33","author":"Larouche\u2010Lebel","year":"2019","journal-title":"J. Vet. Intern. Med."},{"issue":"4","key":"10.1016\/j.bcp.2022.115183_b0245","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1161\/01.HYP.0000237862.94083.45","article-title":"Enalapril attenuates downregulation of Angiotensin-converting enzyme 2 in the late phase of ventricular dysfunction in myocardial infarcted rat","volume":"48","author":"Ocaranza","year":"2006","journal-title":"Hypertension"},{"key":"10.1016\/j.bcp.2022.115183_b0250","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.biopha.2017.05.062","article-title":"ACE-2\/Ang1-7\/Mas cascade mediates ACE inhibitor, captopril, protective effects in estrogen-deficient osteoporotic rats","volume":"92","author":"Abuohashish","year":"2017","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.bcp.2022.115183_b0255","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1177\/1470320314568439","article-title":"Hydronephrosis alters cardiac ACE2 and Mas receptor expression in mice","volume":"16","author":"Zhang","year":"2015","journal-title":"J. Renin. Angiotensin Aldosterone Syst."},{"issue":"4","key":"10.1016\/j.bcp.2022.115183_b0260","doi-asserted-by":"crossref","first-page":"293","DOI":"10.3390\/metabo12040293","article-title":"Ramipril Reduces Acylcarnitines and Distinctly Increases Angiotensin-Converting Enzyme 2 Expression in Lungs of Rats","volume":"12","author":"Kosacka","year":"2022","journal-title":"Metabolites."},{"issue":"5","key":"10.1016\/j.bcp.2022.115183_b0265","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1111\/j.1523-1755.2005.00675.x","article-title":"Effects of renin-angiotensin system blockade on renal angiotensin-(1\u20137) forming enzymes and receptors","volume":"68","author":"Ferrario","year":"2005","journal-title":"Kidney Int."},{"key":"10.1016\/j.bcp.2022.115183_b0270","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.798349","article-title":"Oral Lisinopril Raises Tissue Levels of ACE2, the SARS-CoV-2 Receptor, in Healthy Male and Female Mice","volume":"13","author":"Brooks","year":"2022","journal-title":"Front. Pharmacol."},{"issue":"2","key":"10.1016\/j.bcp.2022.115183_b0275","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1002\/ehf2.13249","article-title":"Influence of renin-angiotensin-aldosterone system inhibitors on plasma levels of angiotensin-converting enzyme 2","volume":"8","author":"Zimmermann","year":"2021","journal-title":"ESC Heart Fail."},{"key":"10.1016\/j.bcp.2022.115183_b0280","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s00380-019-01478-y","article-title":"Relationship between circulating levels of angiotensin-converting enzyme 2-angiotensin-(1\u20137)-MAS axis and coronary heart disease","volume":"35","author":"Zhou","year":"2020","journal-title":"Heart Vessels"},{"key":"10.1016\/j.bcp.2022.115183_b0285","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/jcpt.12625","article-title":"Relationship between genetic variants of ACE2 gene and circulating levels of ACE2 and its metabolites","volume":"43","author":"Chen","year":"2018","journal-title":"J. Clin. Pharm. Ther."},{"key":"10.1016\/j.bcp.2022.115183_b0290","doi-asserted-by":"crossref","first-page":"e29","DOI":"10.1161\/HYPERTENSIONAHA.120.16724","article-title":"Concerns on the Specificity of Commercial ELISAs for the Measurement of Angiotensin (1\u20137) and Angiotensin II in Human Plasma","volume":"77","author":"Chappell","year":"2021","journal-title":"Hypertension"},{"issue":"2","key":"10.1016\/j.bcp.2022.115183_b0295","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1161\/HYPERTENSIONAHA.119.12786","article-title":"Angs (Angiotensins) of the Alternative Renin-Angiotensin System Predict Outcome in Patients With Heart Failure and Preserved Ejection Fraction","volume":"74","author":"Binder","year":"2019","journal-title":"Hypertension"},{"issue":"10","key":"10.1016\/j.bcp.2022.115183_b0300","doi-asserted-by":"crossref","first-page":"166200","DOI":"10.1016\/j.bbadis.2021.166200","article-title":"Novel molecular insights and public omics data in pulmonary hypertension","volume":"1867","author":"Lopez-Crisosto","year":"2021","journal-title":"Biochim. Biophys. Acta, Mol. Basis Dis."},{"issue":"17","key":"10.1016\/j.bcp.2022.115183_b0305","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1016\/j.jacc.2009.01.004","article-title":"ACCF\/AHA 2009 Expert Consensus Document on Pulmonary Hypertension","volume":"53","author":"McLaughlin","year":"2009","journal-title":"J. Am. Coll. Cardiol."},{"issue":"3","key":"10.1016\/j.bcp.2022.115183_b0310","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1165\/ajrcmb.22.3.3701","article-title":"Modulation of angiotensin II receptor expression during development and regression of hypoxic pulmonary hypertension","volume":"22","author":"Chassagne","year":"2000","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"10.1016\/j.bcp.2022.115183_b0315","doi-asserted-by":"crossref","first-page":"3506","DOI":"10.2174\/092986711796642562","article-title":"Local renin-angiotensin II systems, angiotensin-converting enzyme and its homologue ACE2: their potential role in the pathogenesis of chronic obstructive pulmonary diseases, pulmonary hypertension and acute respiratory distress syndrome","volume":"18","author":"Kaparianos","year":"2011","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.bcp.2022.115183_b0320","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.coph.2010.12.002","article-title":"ACE2, a promising therapeutic target for pulmonary hypertension","volume":"11","author":"Shenoy","year":"2011","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.bcp.2022.115183_b0325","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.niox.2019.03.007","article-title":"Angiotensin-(1\u20137) induced vascular relaxation in spontaneously hypertensive rats","volume":"88","author":"Zhang","year":"2019","journal-title":"Nitric Oxide"},{"issue":"6","key":"10.1016\/j.bcp.2022.115183_b0330","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1161\/HYPERTENSIONAHA.114.03871","article-title":"Oral delivery of Angiotensin-converting enzyme 2 and Angiotensin-(1\u20137) bioencapsulated in plant cells attenuates pulmonary hypertension","volume":"64","author":"Shenoy","year":"2014","journal-title":"Hypertension"},{"issue":"9","key":"10.1016\/j.bcp.2022.115183_b0335","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1111\/bph.13044","article-title":"Selective activation of angiotensin AT2 receptors attenuates progression of pulmonary hypertension and inhibits cardiopulmonary fibrosis","volume":"172","author":"Bruce","year":"2015","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.bcp.2022.115183_b0340","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1159\/000346884","article-title":"The changes of serum angiotensin-converting enzyme 2 in patients with pulmonary arterial hypertension due to congenital heart disease","volume":"124","author":"Dai","year":"2013","journal-title":"Cardiology."},{"issue":"1","key":"10.1016\/j.bcp.2022.115183_b0345","doi-asserted-by":"crossref","first-page":"1902416","DOI":"10.1183\/13993003.02416-2019","article-title":"Angiotensin converting enzyme 2 and angiotensin (1\u20137) axis in pulmonary arterial hypertension","volume":"56","author":"Sandoval","year":"2020","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.bcp.2022.115183_b0350","doi-asserted-by":"crossref","first-page":"447","DOI":"10.4196\/kjpp.2018.22.4.447","article-title":"Angiotensin-(1\u20139) ameliorates pulmonary arterial hypertension via angiotensin type II receptor","volume":"22","author":"Cha","year":"2018","journal-title":"Korean J. Physiol. Pharmacol."},{"key":"10.1016\/j.bcp.2022.115183_b0355","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.tips.2015.03.001","article-title":"Angiotensins as therapeutic targets beyond heart disease","volume":"36","author":"Passos-Silva","year":"2015","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.bcp.2022.115183_b0360","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1042\/CS20120030","article-title":"Update on new aspects of the renin-angiotensin system in liver disease: clinical implications and new therapeutic options","volume":"123","author":"Grace","year":"2012","journal-title":"Clin. Sci. (Lond)."},{"issue":"4","key":"10.1016\/j.bcp.2022.115183_b0365","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1053\/j.gastro.2013.06.036","article-title":"Activation of the MAS receptor by angiotensin-(1\u20137) in the renin-angiotensin system mediates mesenteric vasodilatation in cirrhosis","volume":"145","author":"Grace","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bcp.2022.115183_b0370","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1053\/gast.2002.36561","article-title":"Up-regulation of components of the renin-angiotensin system in the bile duct-ligated rat liver","volume":"123","author":"Paizis","year":"2002","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bcp.2022.115183_b0375","doi-asserted-by":"crossref","first-page":"453","DOI":"10.3904\/kjim.2017.317","article-title":"Role of the renin-angiotensin system in hepatic fibrosis and portal hypertension","volume":"33","author":"Shim","year":"2018","journal-title":"Korean J. Intern. Med."},{"issue":"9","key":"10.1016\/j.bcp.2022.115183_b0380","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1038\/mt.2015.92","article-title":"ACE2 Therapy Using Adeno-associated Viral Vector Inhibits Liver Fibrosis in Mice","volume":"23","author":"Mak","year":"2015","journal-title":"Mol. Ther."},{"issue":"9","key":"10.1016\/j.bcp.2022.115183_b0385","doi-asserted-by":"crossref","first-page":"e0138732","DOI":"10.1371\/journal.pone.0138732","article-title":"Hemodynamic Effects of the Non-Peptidic Angiotensin-(1\u20137) Agonist AVE0991 in Liver Cirrhosis","volume":"10","author":"Klein","year":"2015","journal-title":"PLoS ONE"},{"issue":"4","key":"10.1016\/j.bcp.2022.115183_b0390","doi-asserted-by":"crossref","first-page":"702","DOI":"10.3390\/jcm10040702","article-title":"Update on New Aspects of the Renin-Angiotensin System in Hepatic Fibrosis and Portal Hypertension: Implications for Novel Therapeutic Options","volume":"10","author":"Rajapaksha","year":"2021","journal-title":"J. Clin. Med."},{"issue":"2-3","key":"10.1016\/j.bcp.2022.115183_b0395","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.placenta.2005.02.015","article-title":"Distribution of angiotensin-(1\u20137) and ACE2 in human placentas of normal and pathological pregnancies","volume":"27","author":"Vald\u00e9s","year":"2006","journal-title":"Placenta"},{"key":"10.1016\/j.bcp.2022.115183_b0400","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S0303-7207(01)00637-2","article-title":"The upregulation of angiotensin II receptor AT(1) in human preeclamptic placenta","volume":"184","author":"Leung","year":"2001","journal-title":"Mol. Cell. Endocrinol."},{"key":"10.1016\/j.bcp.2022.115183_b0405","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1161\/HYPERTENSIONAHA.117.09386","article-title":"Increased Angiotensin II Sensitivity Contributes to Microvascular Dysfunction in Women Who Have Had Preeclampsia","volume":"70","author":"Stanhewicz","year":"2017","journal-title":"Hypertension"},{"key":"10.1016\/j.bcp.2022.115183_b0410","doi-asserted-by":"crossref","first-page":"241","DOI":"10.3109\/10641955.2015.1009543","article-title":"The effects of gene polymorphisms in angiotensin II receptors on pregnancy-induced hypertension and preeclampsia: a systematic review and meta-analysis","volume":"34","author":"Li","year":"2015","journal-title":"Hypertens Pregnancy."},{"key":"10.1016\/j.bcp.2022.115183_b0415","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1080\/00016340902859307","article-title":"Angiotensin II type 1 and 2 receptors gene polymorphisms in pre-eclampsia and normal pregnancy in three different populations","volume":"88","author":"Akbar","year":"2009","journal-title":"Acta Obstet. Gynecol. Scand."},{"key":"10.1016\/j.bcp.2022.115183_b0420","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.ejogrb.2017.05.011","article-title":"Association of gene polymorphisms of four components of renin-angiotensin-aldosterone system and preeclampsia in South African black women","volume":"215","author":"Aung","year":"2017","journal-title":"Eur. J. Obstet. Gynecol. Reprod. Biol."},{"key":"10.1016\/j.bcp.2022.115183_b0425","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/0090-6980(87)90092-X","article-title":"Prostacyclin and thromboxane release from the vessel wall\u2013comparison between an incubation and a perfusion model","volume":"34","author":"Brunkwall","year":"1987","journal-title":"Prostaglandins"},{"key":"10.1016\/j.bcp.2022.115183_b0430","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1080\/10641955.2018.1460666","article-title":"Association of angiotensin receptor 2 gene polymorphisms with pregnancy induced hypertension risk","volume":"37","author":"Li","year":"2018","journal-title":"Hypertens Pregnancy."},{"key":"10.1016\/j.bcp.2022.115183_b0435","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1113\/jphysiol.2010.203075","article-title":"Angiotensin1-9 antagonises pro-hypertrophic signalling in cardiomyocytes via the angiotensin type 2 receptor","volume":"589","author":"Flores-Munoz","year":"2011","journal-title":"J. Physiol."},{"issue":"4","key":"10.1016\/j.bcp.2022.115183_b0440","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1177\/1753944715597623","article-title":"ACE2 and vasoactive peptides: novel players in cardiovascular\/renal remodeling and hypertension","volume":"9","author":"Mendoza-Torres","year":"2015","journal-title":"Ther. Adv. Cardiovasc. Dis."},{"issue":"1","key":"10.1016\/j.bcp.2022.115183_b0445","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1161\/HYPERTENSIONAHA.116.07572","article-title":"G-Protein-Coupled Receptor MrgD Is a Receptor for Angiotensin-(1\u20137) Involving Adenylyl Cyclase, cAMP, and Phosphokinase A","volume":"68","author":"Tetzner","year":"2016","journal-title":"Hypertension"},{"issue":"7650","key":"10.1016\/j.bcp.2022.115183_b0450","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/nature22035","article-title":"Structural basis for selectivity and diversity in angiotensin II receptors","volume":"544","author":"Zhang","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2022.115183_b0455","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1161\/01.HYP.0000228997.88162.a8","article-title":"Angiotensin II type 2 receptor-bradykinin B2 receptor functional heterodimerization","volume":"48","author":"Abadir","year":"2006","journal-title":"Hypertension"},{"key":"10.1016\/j.bcp.2022.115183_b0460","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1080\/10641950701252827","article-title":"Renal angiotensin-II receptors expression changes in a model of preeclampsia","volume":"26","author":"Anguiano-Robledo","year":"2007","journal-title":"Hypertens Pregnancy."},{"issue":"6","key":"10.1016\/j.bcp.2022.115183_b0465","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1161\/HYPERTENSIONAHA.116.08814","article-title":"Evidence for Heterodimerization and Functional Interaction of the Angiotensin Type 2 Receptor and the Receptor MAS","volume":"69","author":"Leonhardt","year":"2017","journal-title":"Hypertension"},{"key":"10.1016\/j.bcp.2022.115183_b0470","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1161\/01.HYP.0000090323.58122.5C","article-title":"Angiotensin AT2 receptors directly stimulate renal nitric oxide in bradykinin B2-receptor-null mice","volume":"42","author":"Abadir","year":"2003","journal-title":"Hypertension"},{"key":"10.1016\/j.bcp.2022.115183_b0475","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1093\/ajh\/hpw121","article-title":"AT2 Receptors: Potential Therapeutic Targets for Hypertension","volume":"30","author":"Carey","year":"2017","journal-title":"Am. J. Hypertens."},{"key":"10.1016\/j.bcp.2022.115183_b0480","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1161\/01.HYP.0000033224.99806.8A","article-title":"AT2 receptor-mediated relaxation is preserved after long-term AT1 receptor blockade","volume":"40","author":"Widdop","year":"2002","journal-title":"Hypertension"},{"issue":"6551","key":"10.1016\/j.bcp.2022.115183_b0485","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1038\/377748a0","article-title":"Effects on blood pressure and exploratory behaviour of mice lacking angiotensin II type-2 receptor","volume":"377","author":"Ichiki","year":"1995","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.bcp.2022.115183_b0490","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1172\/JCI7886","article-title":"Angiotensin II type 2 receptor overexpression activates the vascular kinin system and causes vasodilation","volume":"104","author":"Tsutsumi","year":"1999","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bcp.2022.115183_b0495","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.phrs.2018.07.022","article-title":"Protection of the myocardium against ischemia\/reperfusion injury by angiotensin-(1\u20139) through an AT2R and Akt-dependent mechanism","volume":"135","author":"Mendoza-Torres","year":"2018","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.bcp.2022.115183_b0500","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1161\/01.HYP.0000164571.77710.19","article-title":"Angiotensin type 2 receptor-mediated phosphorylation of eNOS in the aortas of mice with 2-kidney, 1-clip hypertension","volume":"45","author":"Hiyoshi","year":"2005","journal-title":"Hypertension"},{"key":"10.1016\/j.bcp.2022.115183_b0505","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1161\/01.HYP.0000244108.30909.27","article-title":"Angiotensin II stimulates endothelial NO synthase phosphorylation in thoracic aorta of mice with abdominal aortic banding via type 2 receptor","volume":"48","author":"Yayama","year":"2006","journal-title":"Hypertension"},{"issue":"7","key":"10.1016\/j.bcp.2022.115183_b0510","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1042\/CS20171598","article-title":"Identification of protein phosphatase involvement in the AT2 receptor-induced activation of endothelial nitric oxide synthase","volume":"132","author":"Peluso","year":"2018","journal-title":"Clin. Sci. (Lond)."},{"key":"10.1016\/j.bcp.2022.115183_b0515","doi-asserted-by":"crossref","first-page":"928","DOI":"10.3389\/fphar.2018.00928","article-title":"Cell-Specific Protective Signaling Induced by the Novel AT2R-Agonist NP-6A4 on Human Endothelial and Smooth Muscle Cells","volume":"9","author":"Toedebusch","year":"2018","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.bcp.2022.115183_b0520","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1161\/01.HYP.37.2.301","article-title":"Angiotensin II relaxes microvessels via the AT(2) receptor and Ca(2+)-activated K(+) (BK(Ca)) channels","volume":"37","author":"Dimitropoulou","year":"2001","journal-title":"Hypertension"},{"key":"10.1016\/j.bcp.2022.115183_b0525","first-page":"118","article-title":"Angiotensin type 2-receptor (AT2R) activation induces hypotension in apolipoprotein E-deficient mice by activating peroxisome proliferator-activated receptor-gamma","volume":"6","author":"Li","year":"2016","journal-title":"Am. J. Cardiovasc. Dis."},{"issue":"4","key":"10.1016\/j.bcp.2022.115183_b0530","doi-asserted-by":"crossref","first-page":"e61982","DOI":"10.1371\/journal.pone.0061982","article-title":"Emerging role of angiotensin type 2 receptor (AT2R)\/Akt\/NO pathway in vascular smooth muscle cell in the hyperthyroidism","volume":"8","author":"Carrillo-Sep\u00falveda","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.bcp.2022.115183_b0535","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/fcp.12318","article-title":"Angiotensin-converting enzyme 2-Angiotensin 1\u20137\/1-9 system: novel promising targets for heart failure treatment","volume":"32","author":"Kittana","year":"2018","journal-title":"Fundam. Clin. Pharmacol."},{"key":"10.1016\/j.bcp.2022.115183_b0540","doi-asserted-by":"crossref","first-page":"408","DOI":"10.5271\/sjweh.3960","article-title":"Return-to-work, disabilities and occupational health in the age of COVID-19","volume":"47","author":"Godeau","year":"2021","journal-title":"Scand. J. Work Environ. Health"},{"key":"10.1016\/j.bcp.2022.115183_b0545","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1161\/HYPERTENSIONAHA.120.11941","article-title":"Angiotensin II Type 2 Receptor: A Target for Protection Against Hypertension, Metabolic Dysfunction, and Organ Remodeling","volume":"77","author":"Fatima","year":"2021","journal-title":"Hypertension"},{"issue":"9","key":"10.1016\/j.bcp.2022.115183_b0550","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.1038\/s41418-020-0522-3","article-title":"Angiotensin-(1\u20139) prevents cardiomyocyte hypertrophy by controlling mitochondrial dynamics via miR-129-3p\/PKIA pathway","volume":"27","author":"Sotomayor-Flores","year":"2020","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.bcp.2022.115183_b0555","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.lfs.2017.01.013","article-title":"Early treatment with losartan effectively ameliorates hypertension and improves vascular remodeling and function in a prehypertensive rat model","volume":"173","author":"He","year":"2017","journal-title":"Life Sci."},{"key":"10.1016\/j.bcp.2022.115183_b0560","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1093\/biolre\/ioy179","article-title":"Testosterone plays a permissive role in angiotensin II-induced hypertension and cardiac hypertrophy in male rats","volume":"100","author":"Mishra","year":"2019","journal-title":"Biol. Reprod."},{"key":"10.1016\/j.bcp.2022.115183_b0565","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1097\/FJC.0000000000000042","article-title":"Metoprolol restores expression and vasodilatation function of AT2R in spontaneously hypertensive rats","volume":"63","author":"Li","year":"2014","journal-title":"J. Cardiovasc. Pharmacol."},{"issue":"14","key":"10.1016\/j.bcp.2022.115183_b0570","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1161\/01.CIR.102.14.1684","article-title":"Inhibitory effect of angiotensin II type 2 receptor on coronary arterial remodeling after aortic banding in mice","volume":"102","author":"Akishita","year":"2000","journal-title":"Circulation"},{"issue":"12","key":"10.1016\/j.bcp.2022.115183_b0575","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.52586\/5057","article-title":"Impact of stress and hypertension on the cerebrovasculature","volume":"26","author":"Elsaid","year":"2021","journal-title":"Front. Biosci. (Landmark Ed)."},{"key":"10.1016\/j.bcp.2022.115183_b0580","doi-asserted-by":"crossref","first-page":"628","DOI":"10.52586\/4972","article-title":"The renin-angiotensin system in central nervous system tumors and degenerative diseases","volume":"26","author":"Haron","year":"2021","journal-title":"Front Biosci (Landmark Ed)."},{"key":"10.1016\/j.bcp.2022.115183_b0585","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1161\/HYPERTENSIONAHA.115.03624","article-title":"Angiotensin-II, the Brain, and Hypertension: An Update","volume":"66","author":"Young","year":"2015","journal-title":"Hypertension"},{"issue":"8","key":"10.1016\/j.bcp.2022.115183_b0590","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1007\/s00109-016-1406-3","article-title":"Angiotensin AT2-receptor stimulation improves survival and neurological outcome after experimental stroke in mice","volume":"94","author":"Schwengel","year":"2016","journal-title":"J. Mol. Med. (Berl)."},{"key":"10.1016\/j.bcp.2022.115183_b0595","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1161\/HYPERTENSIONAHA.112.199646","article-title":"Angiotensin II type 2 receptor stimulation initiated after stroke causes neuroprotection in conscious rats","volume":"60","author":"Mccarthy","year":"2012","journal-title":"Hypertension"},{"issue":"4","key":"10.1016\/j.bcp.2022.115183_b0600","doi-asserted-by":"crossref","first-page":"e95762","DOI":"10.1371\/journal.pone.0095762","article-title":"Direct angiotensin AT2 receptor stimulation using a novel AT2 receptor agonist, compound 21, evokes neuroprotection in conscious hypertensive rats","volume":"9","author":"McCarthy","year":"2014","journal-title":"PLoS ONE"},{"key":"10.1016\/j.bcp.2022.115183_b0605","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1007\/s12640-021-00403-4","article-title":"The Protective Effects of AT2R Agonist, CGP42112A, Against Angiotensin II-Induced Oxidative Stress and Inflammatory Response in Astrocytes: Role of AT2R\/PP2A\/NFkappaB\/ROS Signaling","volume":"39","author":"Bhat","year":"2021","journal-title":"Neurotox. Res."},{"issue":"2","key":"10.1016\/j.bcp.2022.115183_b0610","doi-asserted-by":"crossref","first-page":"e0264136","DOI":"10.1371\/journal.pone.0264136","article-title":"Comparative analysis of hypertensive nephrosclerosis in animal models of hypertension and its relevance to human pathology","volume":"17","author":"Gutsol","year":"2022","journal-title":"Glomerulopathy. PLoS One."},{"issue":"11","key":"10.1016\/j.bcp.2022.115183_b0615","doi-asserted-by":"crossref","first-page":"3146","DOI":"10.3390\/cells10113146","article-title":"Molecular Mechanisms of Hypertensive Nephropathy: Renoprotective Effect of Losartan through Hsp70","volume":"10","author":"Costantino","year":"2021","journal-title":"Cells."},{"key":"10.1016\/j.bcp.2022.115183_b0620","doi-asserted-by":"crossref","first-page":"10672","DOI":"10.1038\/s41598-017-09733-w","article-title":"Angiotensin II induces cholesterol accumulation and injury in podocytes","volume":"7","author":"Yang","year":"2017","journal-title":"Sci. Rep."},{"issue":"12","key":"10.1016\/j.bcp.2022.115183_b0625","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1681\/ASN.2019010053","article-title":"Inhibition of Endocytosis of Clathrin-Mediated Angiotensin II Receptor Type 1 in Podocytes Augments Glomerular Injury","volume":"30","author":"Inoue","year":"2019","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.bcp.2022.115183_b0630","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1007\/s11596-021-2368-4","article-title":"Telmisartan Attenuates the Growth of Epithelium-like Cells and Glomerular Injury in Spontaneously Hypertensive Rats","volume":"41","author":"Zhang","year":"2021","journal-title":"Curr. Med. Sci."},{"key":"10.1016\/j.bcp.2022.115183_b0635","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1097\/JCMA.0000000000000600","article-title":"Blood pressure management and renal protection: Revisiting hypertensive nephropathy","volume":"84","author":"Kao","year":"2021","journal-title":"J. Chin. Med. Assoc."},{"key":"10.1016\/j.bcp.2022.115183_b0640","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1161\/HYPERTENSIONAHA.117.09600","article-title":"Deletion of Angiotensin-Converting Enzyme-2 Promotes Hypertensive Nephropathy by Targeting Smad7 for Ubiquitin Degradation","volume":"70","author":"Liu","year":"2017","journal-title":"Hypertension"},{"issue":"22","key":"10.1016\/j.bcp.2022.115183_b0645","doi-asserted-by":"crossref","first-page":"13093","DOI":"10.1111\/jcmm.15914","article-title":"Dual deficiency of angiotensin-converting enzyme-2 and Mas receptor enhances angiotensin II-induced hypertension and hypertensive nephropathy","volume":"24","author":"Ni","year":"2020","journal-title":"J. Cell Mol. Med."},{"key":"10.1016\/j.bcp.2022.115183_b0650","doi-asserted-by":"crossref","unstructured":"X. Jiang, J.M. Eales, D. Scannali, A. Nazgiewicz, P. Prestes, M. Maier, et al., Hypertension and renin-angiotensin system blockers are not associated with expression of angiotensin-converting enzyme 2 (ACE2) in the kidney, Eur. Heart J. 2020;41:4580-4588. http:\/\/dx.doi.org\/10.1093\/eurheartj\/ehaa794.","DOI":"10.1093\/eurheartj\/ehaa794"},{"issue":"1","key":"10.1016\/j.bcp.2022.115183_b0655","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.kint.2018.01.029","article-title":"Novel ACE2-Fc chimeric fusion provides long-lasting hypertension control and organ protection in mouse models of systemic renin angiotensin system activation","volume":"94","author":"Liu","year":"2018","journal-title":"Kidney Int."},{"key":"10.1016\/j.bcp.2022.115183_b0660","doi-asserted-by":"crossref","unstructured":"T.C. Silva De Almeida, K. Lanza, R. Da Silva Filha, C.C. Lmc, E.G. Fonseca, M.W. Chagas, et al., ACE2 activator diminazene aceturate exerts renoprotective effects in gentamicin-induced acute renal injury in ratsm, Clin. Sci. (Lond). 2020;134:3093-3106. http:\/\/dx.doi.org\/10.1042\/CS20201022.","DOI":"10.1042\/CS20201022"},{"key":"10.1016\/j.bcp.2022.115183_b0665","doi-asserted-by":"crossref","first-page":"170746","DOI":"10.1016\/j.peptides.2022.170746","article-title":"Diminazene Aceturate, an angiotensin converting enzyme 2 (ACE2) activator, promotes cardioprotection in ischemia\/reperfusion-induced cardiac injury","volume":"151","author":"Coutinho","year":"2022","journal-title":"Peptides"},{"issue":"4","key":"10.1016\/j.bcp.2022.115183_b0670","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.3390\/ijms23042317","article-title":"Angiotensin Type-2 Receptors: Transducers of Natriuresis in the Renal Proximal Tubule","volume":"23","author":"Carey","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bcp.2022.115183_b0675","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1161\/CIRCRESAHA.119.316193","article-title":"Identification of a Primary Renal AT2 Receptor Defect in Spontaneously Hypertensive Rats","volume":"126","author":"Kemp","year":"2020","journal-title":"Circ. Res."},{"key":"10.1016\/j.bcp.2022.115183_b0680","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1161\/CIRCRESAHA.121.319519","article-title":"Renal AT2 Receptors Mediate Natriuresis via Protein Phosphatase PP2A","volume":"130","author":"Kemp","year":"2022","journal-title":"Circ. Res."},{"key":"10.1016\/j.bcp.2022.115183_b0685","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1161\/HYPERTENSIONAHA.110.164202","article-title":"Angiotensin AT(2) receptor stimulation inhibits early renal inflammation in renovascular hypertension","volume":"57","author":"Matavelli","year":"2011","journal-title":"Hypertension"},{"issue":"2","key":"10.1016\/j.bcp.2022.115183_b0690","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s10278-021-00545-z","article-title":"Detection and Grading of Hypertensive Retinopathy Using Vessels Tortuosity and Arteriovenous Ratio","volume":"35","author":"Badawi","year":"2022","journal-title":"J. Digit. Imaging"},{"issue":"13","key":"10.1016\/j.bcp.2022.115183_b0695","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1042\/CS20160092","article-title":"Hypertensive retinopathy in a transgenic angiotensin-based model","volume":"130","author":"Reichhart","year":"2016","journal-title":"Clin. Sci. (Lond)."},{"key":"10.1016\/j.bcp.2022.115183_b0700","doi-asserted-by":"crossref","DOI":"10.1016\/j.exer.2020.107981","article-title":"Preeclampsia as predisposing factor for hypertensive retinopathy: Participation by the RAAS and angiogenic factors","volume":"193","author":"Ramirez-Montero","year":"2020","journal-title":"Exp. Eye Res."},{"key":"10.1016\/j.bcp.2022.115183_b0705","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/j.cellsig.2012.02.005","article-title":"Angiotensin II modulates VEGF-driven angiogenesis by opposing effects of type 1 and type 2 receptor stimulation in the microvascular endothelium","volume":"24","author":"Carbajo-Lozoya","year":"2012","journal-title":"Cell. Signal."},{"key":"10.1016\/j.bcp.2022.115183_b0710","doi-asserted-by":"crossref","DOI":"10.1016\/j.exer.2019.107770","article-title":"Angiotensin receptor expression revealed by reporter mice and beneficial effects of AT2R agonist in retinal cells","volume":"187","author":"Verma","year":"2019","journal-title":"Exp. Eye Res."},{"key":"10.1016\/j.bcp.2022.115183_b0715","author":"Ocaranza","year":"2015","journal-title":"Patent application US9511120B1."},{"key":"10.1016\/j.bcp.2022.115183_b0720","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1113\/jphysiol.1978.sp012318","article-title":"The half-lives of angiotensin II, angiotensin II-amide, angiotensin III, Sar1-Ala8-angiotensin II and renin in the circulatory system of the rat","volume":"278","author":"Al-Merani","year":"1978","journal-title":"J. Physiol."},{"key":"10.1016\/j.bcp.2022.115183_b0725","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1161\/01.HYP.32.3.496","article-title":"Converting enzyme determines plasma clearance of angiotensin-(1\u20137)","volume":"32","author":"Yamada","year":"1998","journal-title":"Hypertension"},{"issue":"9","key":"10.1016\/j.bcp.2022.115183_b0730","doi-asserted-by":"crossref","first-page":"e45564","DOI":"10.1371\/journal.pone.0045564","article-title":"Adenoviral delivery of angiotensin-(1\u20137) or angiotensin-(1\u20139) inhibits cardiomyocyte hypertrophy via the mas or angiotensin type 2 receptor","volume":"7","author":"Flores-Mu\u00f1oz","year":"2012","journal-title":"PLoS ONE"},{"issue":"24","key":"10.1016\/j.bcp.2022.115183_b0735","doi-asserted-by":"crossref","first-page":"2652","DOI":"10.1016\/j.jacc.2016.09.946","article-title":"Gene Therapy With Angiotensin-(1\u20139) Preserves Left Ventricular Systolic Function After Myocardial Infarction","volume":"68","author":"Fattah","year":"2016","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.bcp.2022.115183_b0740","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.jacc.2016.11.064","article-title":"Roles of Angiotensin Peptides and Recombinant Human ACE2 in Heart Failure","volume":"69","author":"Basu","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.bcp.2022.115183_b0745","article-title":"ACE2 polypeptide","author":"Schuster","year":"2018","journal-title":"Patent application EP12165189A."},{"issue":"1","key":"10.1016\/j.bcp.2022.115183_b0750","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1161\/HYPERTENSIONAHA.109.138420","article-title":"Targeting the degradation of angiotensin II with recombinant angiotensin-converting enzyme 2: prevention of angiotensin II-dependent hypertension","volume":"55","author":"Wysocki","year":"2010","journal-title":"Hypertension"},{"key":"10.1016\/j.bcp.2022.115183_b0755","unstructured":"Glaxosmithkline. The Safety, Tolerability, PK and PD of GSK2586881 in Patients With Acute Lung Injury. 2014. https:\/\/ClinicalTrials.gov\/show\/NCT01597635."},{"key":"10.1016\/j.bcp.2022.115183_b0760","unstructured":"Apeiron-Biologics. Safety and Tolerability Study of APN01 (Recombinant Human Angiotensin Converting Enzyme 2). 2009. https:\/\/ClinicalTrials.gov\/show\/NCT00886353."},{"key":"10.1016\/j.bcp.2022.115183_b0765","doi-asserted-by":"crossref","unstructured":"M.A. Simon, K. Hanrott, D.C. Budd, F. Torres, E. Grunig, P. Escribano-Subias, et al., An open-label, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single doses of GSK2586881 in participants with pulmonary arterial hypertension, Pulm. Circ. 2022;12:e12024. http:\/\/dx.doi.org\/10.1002\/pul2.12024.","DOI":"10.1002\/pul2.12024"},{"key":"10.1016\/j.bcp.2022.115183_b0770","unstructured":"Glaxosmithkline. A Dose-escalation Study in Subjects With Pulmonary Arterial Hypertension (PAH), 2019, https:\/\/ClinicalTrials.gov\/show\/NCT03177603."},{"issue":"7818","key":"10.1016\/j.bcp.2022.115183_b0775","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1038\/s41586-020-2312-y","article-title":"The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice","volume":"583","author":"Bao","year":"2020","journal-title":"Nature"},{"issue":"9","key":"10.1016\/j.bcp.2022.115183_b0780","doi-asserted-by":"crossref","first-page":"5125","DOI":"10.3390\/ijms23095125","article-title":"Angiotensin II Promotes SARS-CoV-2 Infection via Upregulation of ACE2 in Human Bronchial Cells","volume":"23","author":"Caputo","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bcp.2022.115183_b0785","doi-asserted-by":"crossref","first-page":"e34","DOI":"10.1161\/HYPERTENSIONAHA.120.15841","article-title":"Plasma Angiotensin Peptide Profiling and ACE (Angiotensin-Converting Enzyme)-2 Activity in COVID-19 Patients Treated With Pharmacological Blockers of the Renin-Angiotensin System","volume":"76","author":"Kintscher","year":"2020","journal-title":"Hypertension"},{"key":"10.1016\/j.bcp.2022.115183_b0790","doi-asserted-by":"crossref","unstructured":"M. Rieder, L. Wirth, L. Pollmeier, M. Jeserich, I. Goller, N. Baldus, et al. Serum ACE2, Angiotensin II, and Aldosterone Levels Are Unchanged in Patients With COVID-19, Am. J. Hypertens. 2021;34:278-281. http:\/\/dx.doi.org\/10.1093\/ajh\/hpaa169.","DOI":"10.1093\/ajh\/hpaa169"},{"issue":"2","key":"10.1016\/j.bcp.2022.115183_b0795","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1161\/HYPERTENSIONAHA.121.18295","article-title":"Dysregulation of ACE (Angiotensin-Converting Enzyme)-2 and Renin-Angiotensin Peptides in SARS-CoV-2 Mediated Mortality and End-Organ Injuries","volume":"79","author":"Wang","year":"2022","journal-title":"Hypertension"},{"key":"10.1016\/j.bcp.2022.115183_b0800","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1161\/CIRCRESAHA.122.320873","article-title":"Emerging Viral Infections and the Potential Impact on Hypertension, Cardiovascular Disease, and Kidney Disease","volume":"130","author":"Savedchuk","year":"2022","journal-title":"Circ. Res."},{"key":"10.1016\/j.bcp.2022.115183_b0805","doi-asserted-by":"crossref","first-page":"e15230","DOI":"10.15252\/emmm.202115230","article-title":"Clinical grade ACE2 as a universal agent to block SARS-CoV-2 variants","author":"Monteil","year":"2022","journal-title":"EMBO Mol. Med."},{"issue":"1","key":"10.1016\/j.bcp.2022.115183_b0810","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-021-27893-2","article-title":"Circulating ACE2-expressing extracellular vesicles block broad strains of SARS-CoV-2","volume":"13","author":"El-Shennawy","year":"2022","journal-title":"Nat. Commun."},{"issue":"8","key":"10.1016\/j.bcp.2022.115183_b0815","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1016\/j.cell.2021.02.053","article-title":"Soluble ACE2-mediated cell entry of SARS-CoV-2 via interaction with proteins related to the renin-angiotensin system","volume":"184","author":"Yeung","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.bcp.2022.115183_b0820","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1038\/s41467-020-16048-4","article-title":"Neutralization of SARS-CoV-2 spike pseudotyped virus by recombinant ACE2-Ig","volume":"11","author":"Lei","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bcp.2022.115183_b0825","unstructured":"Apeiron-Biologics;, Apeiron-Respiratory-Therapies-Gmb H. Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Inhaled APN01 Developed as Treatment for COVID-19. 2022. https:\/\/ClinicalTrials.gov\/show\/NCT05065645."},{"key":"10.1016\/j.bcp.2022.115183_b0830","unstructured":"The-First-Affiliated-Hospital-of-Guangzhou-Medical-University. Recombinant Human Angiotensin-converting Enzyme 2 (rhACE2) as a Treatment for Patients With COVID-19, 2020, https:\/\/ClinicalTrials.gov\/show\/NCT04287686."},{"key":"10.1016\/j.bcp.2022.115183_b0835","unstructured":"Apeiron-Biologics, Recombinant Human Angiotensin-converting Enzyme 2 (rhACE2) as a Treatment for Patients With COVID-19, 2020, https:\/\/ClinicalTrials.gov\/show\/NCT04335136."},{"key":"10.1016\/j.bcp.2022.115183_b0840","unstructured":"Vicore Pharma AB. A Trial to Investigate Recovery From COVID-19 With C21 in Adult Subjects. 2022. https:\/\/ClinicalTrials.gov\/show\/NCT04880642."},{"key":"10.1016\/j.bcp.2022.115183_b0845","doi-asserted-by":"crossref","first-page":"101152","DOI":"10.1016\/j.eclinm.2021.101152","article-title":"Seven days treatment with the angiotensin II type 2 receptor agonist C21 in hospitalized COVID-19 patients; a placebo-controlled randomised multi-centre double-blind phase 2 trial","volume":"41","author":"Tornling","year":"2021","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.bcp.2022.115183_b0850","unstructured":"A.B. Vicore Pharma, R. Orphan, Safety and Efficacy of C21 in Subjects With COVID-19, 2020, https:\/\/ClinicalTrials.gov\/show\/NCT04452435."},{"issue":"6","key":"10.1016\/j.bcp.2022.115183_b0855","doi-asserted-by":"crossref","first-page":"822","DOI":"10.3390\/pharmaceutics13060822","article-title":"Nanoparticle-Mediated Angiotensin-(1\u20139) Drug Delivery for the Treatment of Cardiac Hypertrophy","volume":"13","author":"Sep\u00falveda-Rivas","year":"2021","journal-title":"Pharmaceutics."},{"key":"10.1016\/j.bcp.2022.115183_b0860","article-title":"Pharmaceutical form fron oral administration of a highly controlled and stable dose of nanoparticles or biomacromolecule suspensions","author":"Morales","year":"2019","journal-title":"Patent application US 2019\/0015320"},{"key":"10.1016\/j.bcp.2022.115183_b0865","article-title":"Cyclic angiotensin analogs","author":"Haas","year":"2011","journal-title":"Patent application NZ574876A."},{"key":"10.1016\/j.bcp.2022.115183_b0870","article-title":"Angiotensin-(1\u20139) analogue based on D-aminoacids, pharmaceutical compositions and uses thereof","author":"Ocaranza","year":"2021","journal-title":"Patent application PCT\/IB2021\/054074."},{"key":"10.1016\/j.bcp.2022.115183_b0875","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/0167-0115(93)90244-3","article-title":"Agonistic and antagonistic properties of angiotensin analogs at the AT2 receptor in PC12W cells","volume":"44","author":"Brechler","year":"1993","journal-title":"Regul. Pept."},{"key":"10.1016\/j.bcp.2022.115183_b0880","doi-asserted-by":"crossref","unstructured":"E.S. Jones, Y. Wang, M. Del Borgo, K.M. Denton, M.-I. Aguilar, R.E. Widdop, Chapter 19 - Angiotensin-Based Peptides asAT2RAgonists, in: T. Unger, U.M. Steckelings, R.A.S. dos Santos (Eds.), The Protective Arm of the Renin Angiotensin System (RAS), Academic Press, Boston, 2015, pp. 141-147.","DOI":"10.1016\/B978-0-12-801364-9.00019-5"},{"key":"10.1016\/j.bcp.2022.115183_b0885","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1038\/ki.2013.193","article-title":"Chronic AT2 receptor activation increases renal ACE2 activity, attenuates AT1 receptor function and blood pressure in obese Zucker rats","volume":"84","author":"Ali","year":"2013","journal-title":"Kidney Int."},{"key":"10.1016\/j.bcp.2022.115183_b0890","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1038\/sj.bjp.0705838","article-title":"AT2 receptor-mediated vasodilatation is unmasked by AT1 receptor blockade in conscious SHR","volume":"142","author":"Li","year":"2004","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.bcp.2022.115183_b0895","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.peptides.2013.06.008","article-title":"Angiotensin AT2 receptor agonist stimulates high stretch induced- ANP secretion via PI3K\/NO\/sGC\/PKG\/pathway","volume":"47","author":"Gao","year":"2013","journal-title":"Peptides"},{"issue":"24","key":"10.1016\/j.bcp.2022.115183_b0900","doi-asserted-by":"crossref","first-page":"5995","DOI":"10.1021\/jm049715t","article-title":"Design, synthesis, and biological evaluation of the first selective nonpeptide AT2 receptor agonist","volume":"47","author":"Wan","year":"2004","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bcp.2022.115183_b0905","doi-asserted-by":"crossref","first-page":"F1379","DOI":"10.1152\/ajprenal.00002.2015","article-title":"Angiotensin AT2 receptor agonist prevents salt-sensitive hypertension in obese Zucker rats","volume":"308","author":"Ali","year":"2015","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"10.1016\/j.bcp.2022.115183_b0910","doi-asserted-by":"crossref","first-page":"3981790","DOI":"10.1155\/2016\/3981790","article-title":"Central Infusion of Angiotensin II Type 2 Receptor Agonist Compound 21 Attenuates DOCA\/NaCl-Induced Hypertension in Female Rats","volume":"2016","author":"Dai","year":"2016","journal-title":"Oxid. Med. Cell. Longev."},{"key":"10.1016\/j.bcp.2022.115183_b0915","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1161\/CIRCRESAHA.116.308384","article-title":"AT2 Receptor Activation Prevents Sodium Retention and Reduces Blood Pressure in Angiotensin II-Dependent Hypertension","volume":"119","author":"Kemp","year":"2016","journal-title":"Circ. Res."},{"issue":"3","key":"10.1016\/j.bcp.2022.115183_b0920","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1161\/HYPERTENSIONAHA.112.196022","article-title":"Compound 21 induces vasorelaxation via an endothelium- and angiotensin II type 2 receptor-independent mechanism","volume":"60","author":"Verdonk","year":"2012","journal-title":"Hypertension"},{"key":"10.1016\/j.bcp.2022.115183_b0925","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1161\/HYPERTENSIONAHA.112.00762","article-title":"Angiotensin II type 2 receptor-mediated and nitric oxide-dependent renal vasodilator response to compound 21 unmasked by angiotensin-converting enzyme inhibition in spontaneously hypertensive rats in vivo","volume":"62","author":"Brouwers","year":"2013","journal-title":"Hypertension"},{"issue":"8","key":"10.1016\/j.bcp.2022.115183_b0930","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.1210\/en.2016-1131","article-title":"Angiotensin Type-2 Receptors Influence the Activity of Vasopressin Neurons in the Paraventricular Nucleus of the Hypothalamus in Male Mice","volume":"157","author":"de Kloet","year":"2016","journal-title":"Endocrinology"},{"issue":"3","key":"10.1016\/j.bcp.2022.115183_b0935","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.peptides.2007.11.017","article-title":"Hypotensive activity of novokinin, a potent analogue of ovokinin(2\u20137), is mediated by angiotensin AT(2) receptor and prostaglandin IP receptor","volume":"29","author":"Yamada","year":"2008","journal-title":"Peptides"},{"key":"10.1016\/j.bcp.2022.115183_b0940","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.3906\/sag-1502-18","article-title":"The effects of novokinin, an AT2 agonist, on blood pressure, vascular responses, and levels of ADMA, NADPH oxidase, and Rho kinase in hypertension induced by NOS inhibition and salt","volume":"46","author":"Mutlu","year":"2016","journal-title":"Turk. J. Med. Sci."},{"key":"10.1016\/j.bcp.2022.115183_b0945","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1016\/j.pharep.2014.04.013","article-title":"Vascular effects of a tripeptide fragment of novokinine in hypertensive rats: Mechanism of the hypotensive action","volume":"66","author":"Badzynska","year":"2014","journal-title":"Pharmacol. Rep."},{"issue":"5","key":"10.1016\/j.bcp.2022.115183_b0950","doi-asserted-by":"crossref","first-page":"L341","DOI":"10.1152\/ajplung.00360.2012","article-title":"Agonists of MAS oncogene and angiotensin II type 2 receptors attenuate cardiopulmonary disease in rats with neonatal hyperoxia-induced lung injury","volume":"305","author":"Wagenaar","year":"2013","journal-title":"Am. J. Physiol. Lung Cell. Mol. Physiol."},{"key":"10.1016\/j.bcp.2022.115183_b0955","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1161\/HYPERTENSIONAHA.110.164301","article-title":"A single beta-amino acid substitution to angiotensin II confers AT2 receptor selectivity and vascular function","volume":"57","author":"Jones","year":"2011","journal-title":"Hypertension"},{"issue":"7","key":"10.1016\/j.bcp.2022.115183_b0960","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1021\/cb500063y","article-title":"Electronic sculpting of ligand-GPCR subtype selectivity: the case of angiotensin II","volume":"9","author":"Magnani","year":"2014","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.bcp.2022.115183_b0965","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1042\/CS20200153","article-title":"Renal functional effects of the highly selective AT2R agonist, beta-Pro7 Ang III, in normotensive rats","volume":"134","author":"Krause","year":"2020","journal-title":"Clin. Sci. (Lond)."},{"key":"10.1016\/j.bcp.2022.115183_b0970","doi-asserted-by":"crossref","first-page":"7393","DOI":"10.1111\/jcmm.15342","article-title":"AT2R agonist NP-6A4 mitigates aortic stiffness and proteolytic activity in mouse model of aneurysm","volume":"24","author":"Sharma","year":"2020","journal-title":"J. Cell Mol. Med."},{"key":"10.1016\/j.bcp.2022.115183_b0975","doi-asserted-by":"crossref","first-page":"115859","DOI":"10.1016\/j.bmc.2020.115859","article-title":"N-(Methyloxycarbonyl)thiophene sulfonamides as high affinity AT2 receptor ligands","volume":"29","author":"Wannberg","year":"2021","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bcp.2022.115183_b0980","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2022.116790","article-title":"Angiotensin II AT2 receptor ligands with phenylthiazole scaffolds","volume":"65","author":"Gopalan","year":"2022","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bcp.2022.115183_b0985","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2022.116804","article-title":"2-Alkyl substituted benzimidazoles as a new class of selective AT2 receptor ligands","volume":"66","author":"Roy","year":"2022","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bcp.2022.115183_b0990","unstructured":"Vicore Pharma AB, Ab CTCCTC. Effect of C21 on Forearm Blood Flow. 2022. https:\/\/ClinicalTrials.gov\/show\/NCT05277922."},{"key":"10.1016\/j.bcp.2022.115183_b0995","unstructured":"Vicore Pharma AB, Orphan R. Safety, Efficacy and Pharmacokinetics of C21 in Subjects With IPF. 2022. https:\/\/ClinicalTrials.gov\/show\/NCT04533022."},{"key":"10.1016\/j.bcp.2022.115183_b1000","unstructured":"Vicore Pharma AB, Sgs Life Sciences ADOSGSBNV. Cold Challenge With C21 in RP. 2020. https:\/\/ClinicalTrials.gov\/show\/NCT04388176."},{"key":"10.1016\/j.bcp.2022.115183_b1005","unstructured":"Alan R, Quotient C, Lanthiopep BV. First in Human Single Ascending Dose Study of MOR107. 2017. https:\/\/ClinicalTrials.gov\/show\/NCT03067363."},{"key":"10.1016\/j.bcp.2022.115183_b1010","unstructured":"Glaxosmithkline. Study of GSK2586881 on Acute Hypoxia and Exercise. 2019. https:\/\/ClinicalTrials.gov\/show\/NCT03000686."},{"issue":"6","key":"10.1016\/j.bcp.2022.115183_b1015","doi-asserted-by":"crossref","first-page":"1702638","DOI":"10.1183\/13993003.02638-2017","article-title":"A potential therapeutic role for angiotensin-converting enzyme 2 in human pulmonary arterial hypertension","volume":"51","author":"Hemnes","year":"2018","journal-title":"Eur. Respir. J."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295222002775?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295222002775?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T13:41:44Z","timestamp":1757770904000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295222002775"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":203,"alternative-id":["S0006295222002775"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2022.115183","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Angiotensin-(1\u20139) in hypertension","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2022.115183","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"115183"}}